MX2022000069A - Formas sólidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il )-1-oxo 2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y métodos para prepararlas. - Google Patents

Formas sólidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il )-1-oxo 2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y métodos para prepararlas.

Info

Publication number
MX2022000069A
MX2022000069A MX2022000069A MX2022000069A MX2022000069A MX 2022000069 A MX2022000069 A MX 2022000069A MX 2022000069 A MX2022000069 A MX 2022000069A MX 2022000069 A MX2022000069 A MX 2022000069A MX 2022000069 A MX2022000069 A MX 2022000069A
Authority
MX
Mexico
Prior art keywords
oxo
diazaspiro
carboxylate
tert
hydroxy
Prior art date
Application number
MX2022000069A
Other languages
English (en)
Inventor
Shaoxin Feng
Xiaoda Yuan
William R Perrault
Danny T Dinh
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of MX2022000069A publication Critical patent/MX2022000069A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Formas en estado sólido de (S)-2-((2S,3R)-1-amino-3-hidroxi-1-oxob utan-2-il)-1-oxo 2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo, composiciones farmacéuticas, preparación y usos de las mismas.
MX2022000069A 2019-06-24 2020-06-23 Formas sólidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il )-1-oxo 2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y métodos para prepararlas. MX2022000069A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962865826P 2019-06-24 2019-06-24
PCT/US2020/039163 WO2020263847A1 (en) 2019-06-24 2020-06-23 Solid forms of tert-butyl (s)-2-((2s,3r) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them

Publications (1)

Publication Number Publication Date
MX2022000069A true MX2022000069A (es) 2022-05-24

Family

ID=74060350

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000069A MX2022000069A (es) 2019-06-24 2020-06-23 Formas sólidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il )-1-oxo 2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y métodos para prepararlas.

Country Status (12)

Country Link
US (1) US20220267341A1 (es)
EP (1) EP3986399A4 (es)
JP (1) JP2022539342A (es)
KR (1) KR20220061088A (es)
CN (1) CN114364380A (es)
AU (1) AU2020304001A1 (es)
BR (1) BR112021026380A2 (es)
CA (1) CA3144600A1 (es)
IL (1) IL289198A (es)
MA (1) MA56550A (es)
MX (1) MX2022000069A (es)
WO (1) WO2020263847A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56551A (fr) * 2019-06-24 2022-04-27 Naurex Inc Procédés et intermédiaires pour la production de composés de diazaspiro-lactame

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1916241B1 (en) * 2005-06-21 2013-06-12 Ajinomoto Co., Inc. Crystal of phenylalanine derivative, process for producing the same and use thereof
WO2010033757A1 (en) * 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
MX2015009773A (es) * 2013-01-29 2016-08-05 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
BR112015018087B1 (pt) * 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos
PT3436463T (pt) * 2016-03-28 2021-09-06 Takeda Pharmaceuticals Co Formas cristalinas de 2-[(2s)-1-azabiciclo[2.2.2]oct-2- il]-6-(3-metil-1h-pirazol-4-il)tieno[3,2-d]pirimidin-4(3h)- ona hemihidratada
PE20190174A1 (es) * 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
MA56551A (fr) * 2019-06-24 2022-04-27 Naurex Inc Procédés et intermédiaires pour la production de composés de diazaspiro-lactame

Also Published As

Publication number Publication date
EP3986399A4 (en) 2023-06-07
US20220267341A1 (en) 2022-08-25
EP3986399A1 (en) 2022-04-27
IL289198A (en) 2022-02-01
JP2022539342A (ja) 2022-09-08
KR20220061088A (ko) 2022-05-12
AU2020304001A1 (en) 2022-01-27
CN114364380A (zh) 2022-04-15
WO2020263847A1 (en) 2020-12-30
MA56550A (fr) 2022-04-27
BR112021026380A2 (pt) 2022-05-10
CA3144600A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
AU2018271990A1 (en) Covalent inhibitors of KRAS
MX2021009259A (es) Conjugados de il-2 y metodos de uso del mismo.
EP4248965A3 (en) Compounds, compositions and methods
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MX2022010515A (es) Conjugacion mediada por transglutaminasa.
MX2021009669A (es) Compuestos, composiciones y métodos.
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
CR20200445A (es) Inhibidores de la arginasa
AU2016335612B2 (en) Dental composition
MX2020010116A (es) Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
MX2022006807A (es) Análogos de rapamicina y usos de estos.
PH12021550048A1 (en) Selective estrogen receptor degraders.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2021003180A (es) Métodos y kits para preparar sangre entera con inactivación de patógenos.
MX2022000069A (es) Formas sólidas de (s)-2-((2s,3r)-1-amino-3-hidroxi-1-oxobutan-2-il )-1-oxo 2,5-diazaspiro[3.4]octano-5-carboxilato de terc-butilo y métodos para prepararlas.
WO2020146700A8 (en) Lipid nanoparticles
WO2019229536A3 (en) Novel benzodiazepine derivatives and uses thereof
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
MX2022001694A (es) Metodos y composiciones para mejorar el rendimiento de soya.
AU2018279184A1 (en) Anti-TrkB antibodies
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline
EP4026538A4 (en) OPHTHALMIC PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARATION THEREOF AND USE THEREOF